Methods are provided for conducting chronic myelogenous leukemia (CML) assays to detect or monitor CML cells in a human patient. A sample is obtained from the patient and total RNA is extracted. The extracted RNA is contacted with appropriate primers that surround the bcr2-abl2 or the bcr3-abl2 translocation regions of the Philadelphia chromosome, and the inter-primer regions are amplified. After amplification, the reaction product, if any, is captured onto a solid phase by means of a capture agent and is detected by means of a labelled detector agent. The amount of labelled detector agent is correlated with the presence or quantity of CML cells in the patient.
展开▼
